New cell therapy takes on tough stomach and colon cancers
Disease control
Not yet recruiting
This early-phase study tests a new cell therapy called NK510 in 15 people with advanced stomach or colon cancer that has not responded to standard treatments. The therapy is given through an IV or directly into the belly to see if it is safe and can shrink tumors. The goal is to …
Phase: EARLY_PHASE1 • Sponsor: Base Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC